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ABSTRACT  
Aims: Determine the prevalence and severity of diabetic retinopathy and risk factors in 
a large community based screening programme, in order to accurately estimate the 
future burden of this specific and debilitating complication of diabetes.   
 
Methods: A cross-sectional analysis of 91,393 persons with diabetes, 5,003 type 1 
diabetes and 86,390 type 2 diabetes, at their first screening by the community based 
National Diabetic Retinopathy Screening Service for Wales from 2005 to 2009.  Image 
capture utilised 2x45° digital images per eye following mydriasis, classified by 
qualified retinal graders with final grading based on the worst eye. 
Results: The prevalence of any diabetic retinopathy and sight-threatening diabetic 
retinopathy in those with type 1 diabetes was 56.0% and 11.2% respectively and in type 
2 diabetes was 30.3% and 2.9% respectively.  The presence of diabetic retinopathy both 
non-sight-threatening and sight-threatening was strongly associated with increasing 
duration of diabetes for either type 1 and type 2 diabetes and also associated with 
insulin therapy in those with type 2 diabetes.  
Conclusions: Prevalence of diabetic retinopathy within the largest reported community-
based, quality assured, diabetic retinopathy screening programme, was higher in persons 
with type 1 diabetes however, the major burden is represented by type 2 diabetes being 
94% of the screened population.   
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INTRODUCTION 
Diabetic retinopathy (DR) continues to be an important microvascular complication in both 
type 1 and type 2 diabetes.  Previous evidence suggests that DR is evident in approximately 
50% of persons with type 1 diabetes for 28 years and advanced DR after 39 years. (1)  In 
contrast about 12-19%%,(2, 3) of persons with type 2 diabetes have some DR already at the 
time of diagnosis,(4) with 4% of developing proliferative DR after 20 years or more of 
diabetes.(2)  In both the UK and USA, DR unfortunately remains among the leading causes 
of blindness and low vision, along with age related macular degeneration and glaucoma.(5-8) 
 
The St Vincent Declaration (1989) recommended that new onset blindness arising from DR 
should be reduced by one third within five years.(9)  However, it is only in the last decade 
that significant progress has been made in implementing screening programmes to detect and 
monitor DR.  To date many different DR screening models have been introduced 
worldwide.(10-19)  In the UK the National Screening Committee (NSC) for England and 
Wales (1999) produced guidelines for DR screening programmes to ensure standardisation 
and quality assurance.  The recommended screening procedure includes assessment of visual 
acuity and obtaining digital fundal photographs following mydriasis,(20) in persons aged 12 
years and older.(21)  The recommendation of screening beginning from the age of 12 years 
reflects  the low incidence of DR, and especially proliferative DR, in younger children.(22)  
In Scotland a three tiered screening approach has been implemented which involves obtaining 
only one macular centred digital fundal photograph per eye without mydriasis (tier 1) and if 
unsuccessful then mydriasis is used (tier 2) and finally biomicroscopy with a slit lamp if 
photography remains unsuccessful (tier 3).(23) 
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Wales currently has a population of  3.06 million is predominantly Caucasian, with the 
majority situated in the industrial south (~60%) with the remainder of the country generally 
regarded as rural.(24) The prevalence of diabetes in Wales is currently estimated at 
approximately 5%, 160,000 people affected.(25)  Following a pilot regional programme,(26) 
a national DR screening programme, the Diabetic Retinopathy Screening Service for Wales 
(DRSSW) was commissioned in 2002.  The aim of the service was initially to identify all 
undiagnosed sight-threatening DR and facilitate timely onwards referral to hospital eye 
services (HES).  The secondary aim was to identify the presence of any DR so that 
improvements in glycaemic control, hypertension and dyslipidaemia could be implemented 
where necessary.(20) 
 
The prevalence of DR has previously been described for several populations,(8, 27) using 
different methods for the detection and classification of DR which accounts in part for the 
broad variations observed.  A recent systematic review,(27) conducted an individual 
participant analysis to estimate the global prevalence of DR and also to determine the major 
risk factors by pooling a total 35 studies (22,896 people) conducted between 1980 and 2008 
in the USA, Australia, Europe and Asia.  The studies obtained retinal photographs using a 
mixture of 35mm film and digital images, through dilated and undilated pupils capturing 
between one and nine fields per eye with a minority photographing one eye only.  There were 
also  several different grading protocols used to ascertain the prevalence and severity of DR.   
 
The objective of our study was to accurately determine the prevalence of DR at entry into a 
National screening programme utilising standardised protocols and quality assured 
methodology for both photography and grading and also to explore the relationship between 
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certain putative risk factors with the presence of any lesions of DR and also the presence of 
sight-threatening DR in persons with type 1diabetes and type 2 diabetes. 
 MATERIALS AND METHODS 
 
The Diabetic Retinopathy Screening Service for Wales (DRSSW) is a community based 
mobile screening service.  Visual acuity is recorded (achieved with or without glasses or with 
pinhole) using a 3m illuminated Snellen chart and two 45° fields (one macula centred and one 
nasal) digital fundal photographs are captured following mydriasis (1% tropicamide) 
followed by grading by accredited retinal graders.  Images are stored on laptop computers 
and then downloaded daily onto a central server, either directly or via a secure internet 
connection.  The DRSSW employs 30 photographic teams consisting of a health care 
professional and accredited photographer who conduct the screening at 220 locations 
throughout Wales.  The Canon DGi digital camera is used to acquire the digital images which 
are centrally graded using a standardised grading protocol (table 1).  All the key elements are 
subject to quality control procedures.  At the time of screening all persons are asked to sign a 
two part consent form.  The first part is to give consent mydriasis to be instilled and for 
retinal photographs to be taken.  The second part is for consent for their anonymised data and 
images to be used for teaching and research purposes.  Only the data for those individuals  
who provided both consents were included in this study. 
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Table 1 A comparison of grading protocols for diabetic retinopathy 
 Key: ETDRS – Early treatment of diabetic retinopathy study; NSC – National Screening 
Committee (UK); DRSSW – Diabetic retinopathy screening service for Wales 
 
 
Persons with diabetes aged 12 years or above who are registered with a general practice (GP) 
in Wales and not already under the care of HES for DR related reasons, are required to be 
referred to the DRSSW accompanied by demographic and diagnostic information.  These 
referrals from GP's form the single collated list of persons for screening.  On a monthly basis 
the lists are complied and sent to each GP practice for validation.  8.4% of those known to 
have diabetes in Wales were ineligible for screening as 6.5% were already under the care of 
HES for DR related reasons, 1.6%  were excluded due to medical reasons and 0.4% were 
under the age of 12 years (19.3% of those who were eligible for screening did not attend 
appointments).  All persons invited for screening are sent an appointment letter with a date, 
time and venue for screening.  All letters have a reminder that all appointments and venue 
can be changed to a time and place more suitable for the individual.  The DRSSW currently 
(2013) has an uptake rate of 80% for screening.  Any person who does not attend a screening 
appointment are sent additional appointments within 3 months and their GP's are informed of 
ETDRS scale(28) NSC(29) DRSSW 
10 No Diabetic 
Retinopathy 
RO No Diabetic 
Retinopathy 
RO No Diabetic 
Retinopathy 
20 - 35 Very mild – Mild 
Non Proliferative 
Diabetic 
Retinopathy 
R1 Background Diabetic 
Retinopathy 
R1.1 
 
Minimal Background 
Diabetic Retinopathy 
R1.2 Moderate Background 
Diabetic Retinopathy 
43 - 53 Moderate – Severe 
Non Proliferative 
Diabetic 
Retinopathy 
R2 Preproliferative 
Diabetic Retinopathy 
R2 Preproliferative 
Diabetic Retinopathy 
≥61 Proliferative 
Diabetic 
Retinopathy 
R3 Proliferative Diabetic 
Retinopathy 
R3 Proliferative Diabetic 
Retinopathy 
  M0 No Maculopathy M0 No Maculopathy 
M1 Maculopathy M1 Possible Maculopathy 
M2 Definite Maculopathy 
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their non-attendance and are asked to remind their patients of the importance of attending 
screening.  
 
DRSSW utilise a grading protocol which evolved from the European handbook for 
screening(9) and all subsequent changes were made by consensus with ophthalmologists 
across Wales as part of the All Wales Ophthalmology group who provide advice and 
guidance to the DRSSW on DR and referrals to the HES. Subjects with DR were sub-divided 
into two groups: non sight-threatening DR (NSTDR) which included those with background 
DR (BDR) and pre-proliferative DR (PPDR); and sight-threatening DR (STDR) i.e. 
maculopathy and/or proliferative DR (Table 1).  As retinal thickening or clinically significant 
macular oedema is not discernible on non-stereoscopic images, maculopathy was defined as 
definite exudates or haemorrhages (with an unexplained VA of worse than 6/12) within 1 disc 
diameter of the fovea.  Both eyes were assessed for DR and the worse grade from the two 
eyes used in the analysis.  All persons with unassessable images in one or both eyes that had 
not previously been seen by an ophthalmologist were referred to HES for assessment.  Where 
only one eye was assessable the presence or absence of DR relied on this eye as was the 
grading of DR if present.  The NSC definition of unassessable images is used by the 
DRSSW.(30) 
 
Characteristics of the study population were described using means (SD) for continuous 
variables with percentages for categorical variables.  For comparisons, T-tests and chi-
squared tests were used respectively with a p-value of <0.05 used to indicate statistical 
significance.  Logistic regression analyses were performed to assess the association of the 
routinely collected variables with retinopathy status, separately for each type of diabetes.  
The continuous variables of age at diagnosis of diabetes and duration of diabetes were 
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categorised to avoid assuming linearity, with different categories used for type 1 and type 2 
diabetes to ensure equal distribution among the groups.  For type 1 diabetes, age at diagnosis 
was divided into sub groups ≤12 yrs, 13 to 23 yrs and ≥24 yrs and diabetes duration into sub 
groups <10 yrs, 10 to 19 yrs and ≥20 years.  For type 2 diabetes the sub groups for age at 
diagnosis were ≤55 yrs, 56 to 66 yrs and ≥67 yrs and for diabetes duration were <5 years, 5 to 
9 years and ≥10 years respectively.  Odds ratios (OR) and 95% confidence intervals (CI) for 
each were calculated.  
 
RESULTS  
From January 2005 to November 2009, 91,393 persons with type 1 or type 2 diabetes were 
screened by the DRSSW.  The demographic characteristics of the participants are in included 
in table 2. The overall prevalence of any DR within this population was 32.4% (95% CI 32.1, 
32.7), NSTDR 29.0% (95% CI 28.7, 29.3) and STDR 3.4% (95% CI 3.3, 3.5).  The 
prevalence of any DR was 56.3%  in persons with type 1 diabetes and 30.9%  in persons with 
type 2 diabetes.  NSTDR prevalence was 45.1% in type 1 diabetes and 28.1% in type 2 
diabetes.  For STDR the prevalence in type 1 diabetes was 11.2% and in type 2 diabetes was 
2.9%.  The prevalence’s of the different categories of DR are shown in table 2.
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Table 2 Characteristics of study participants at the occasion of first screening event. 
 Type 1 diabetes Type 2 diabetes 
n 5,003 86,390 
Age years  36.5 (16.4) 65.3 (11.7) 
Gender n (%):   
Male 2,721 (54.7)   48,490 (56.4)   
Female 2,257 (45.3) 37,446 (43.6)  
Known duration of diabetes 
years  
16.7 (13.2) 5.3 (5.6) 
Treatment of diabetes:   
Diet only 0 26,025 (30.5) 
OHA  0 51,071 (59.9) 
Insulin  5,003 (100) 8,226 (9.5) 
Age at diagnosis of diabetes 
years  
19.7 (13.7) 60.0 (11.9) 
Unassessable images  
% (95% CI) 
0.5 (0.3, 0.7) 2.1 (2.0, 2.2) 
DR status: % (95% CI)   
No DR 43.8 (42.4, 45.1) 69.0 (68.7, 69.3) 
BDR 39.8 (38.4, 41.2) 26.5 (26.3, 26.9) 
PPDR only 5.2 (4.6, 5.9) 1.5 (1.4, 1.6) 
NSTDR 45.1 (43.7, 46.4) 28.1 (27.8, 28.4) 
Maculopathy (with BDR) 4.2 (3.7, 4.8) 1.4 (1.3, 1.5) 
PPDR with maculopathy 2.9 (2.5, 3.4) 0.97 (0.91, 1.04) 
PDR only 2.6 (2.2, 3.1) 0.31 (0.28, 0.35) 
PDR with maculopathy 1.5 (1.2, 1.9) 0.23 (0.20, 0.27) 
STDR 11.2 (10.4, 12.1) 2.9  (2.8, 3.0) 
      Some subjects had missing values for gender and treatment. Numbers are mean (±SD) or   
      n (%) unless otherwise stated  Key:  diabetes – Diabetes mellitus; OHA – Oral  
      hypoglycaemic agents; 95% CI – 95% confidence intervals; No DR - No evidence of   
     diabetic retinopathy; BDR – Background diabetic retinopathy; PPDR – Pre-proliferative  
     diabetic retinopathy; NSTDR – Non sight-threatening diabetic retinopathy; PPDR with  
     maculopathy – pre-proliferative diabetic retinopathy with exudates less than 1 disc  
     diameter from the fovea; PDR – Proliferative diabetic retinopathy;  PDR with  
     maculopathy – Proliferative diabetic retinopathy with exudates within 1 disc diameter of  
     the fovea; STDR – Sight-threatening diabetic retinopathy.  
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The characteristics of subjects with and without DR at initial screening are compared in table 
3, with the former group divided into NSTDR and STDR.  In subjects with Type 1 diabetes, 
those with STDR were more likely to be male, younger at the time of diagnosis, with a longer 
duration of diabetes and therefore older at first screening compared to those without DR.  
Participants with type 2 diabetes and STDR were also more likely to be male, younger at both 
the screening event and diagnosis of diabetes, with a longer duration of diabetes and in 
addition were more likely to be receiving insulin therapy compared to those without DR. 
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Table 3 Characteristics for subjects with type 1 and 2 diabetes presenting either without DR, with any DR, NSTDR or STDR . 
 Type 1 diabetes Type 2 diabetes 
 NDR 
(Reference) 
Any DR  NSTDR STDR  NDR 
(Reference) 
Any DR 
 
NSTDR  
 
STDR  
 
n 2,177 2,802 2,243 559 58,389 26,216 23,763 2,453 
Age years  34.5 (19.2) 37.9 (13.5)* 37.5 (14.0)* 39.1 (11.5)* 64.6 (11.7) 66.3 (11.4)* 66.6 (11.5)* 64.0 (10.9)* 
Gender       * * * 
Male  1,182 (54.5) 1,524 (54.7) 1,170 (52.5) 354 (63.4)* 32,162 (55.4) 15,425 (59.1) 13,908 (58.8) 1,517 (62.0) 
Female  985 (45.5) 1,264 (45.3) 1,060 (47.5) 204 (36.6) 25,886 (44.6) 10,684 (40.9) 9,753 (41.2) 931 (38.0) 
Duration of diabetes 
years  
9.4 (10.5) 
 
22.3 (12.2)* 21.9 (12.6)* 24.2 (10.5)* 4.3 (4.5) 7.6 (6.8)* 7.4 (6.6)* 10.4 (7.5)* 
Treatment of diabetes      * * * * 
Diet only N/A N/A N/A N/A 20,379 (35.3) 5,078 (19.6) 4,873 (20.8) 205 (8.5) 
OHA N/A N/A N/A N/A 33,578 (58.2) 16,446 (63.6) 14,941 (63.7) 1,505 (62.0) 
Insulin N/A N/A N/A N/A 3,744 (6.5) 4,339 (16.8) 3,625 (15.5) 714 (29.5) 
Age at diagnosis of 
diabetes years  
25.2 (17.2) 15.5 (7.9)* 15.7 (7.9)* 14.9 (7.9)* 60.3 (11.7)* 58.7 (12.1)* 59.2 (12.0)* 53.5 (11.8)* 
Numbers are mean (±SD) or n(%). Key: *P values <0.0001; N/A not applicable; diabetes – Diabetes mellitus; OHA – Oral hypoglycaemic agents; NDR - No 
evidence of diabetic retinopathy; Any DR – any diabetic retinopathy; NSTDR – Non sight-threatening diabetic retinopathy; STDR – Sight-threatening diabetic 
retinopathy
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The results of the logistic regression analysis are shown in Table 4.  For type 1 diabetes 
subjects the odds ratio for each type of DR was significantly higher in those aged 12 to 23 
years at diagnosis and significantly lower in those aged over 23 years when compared to 
those aged below 12 at diagnosis.  Males also had an increased odds of all severities of DR 
compared to females.  The odds ratio of all severity grades of DR increased sharply with 
duration of diabetes.  There was a 7.90 and 20.60 fold increased odds of any DR associated 
with a duration of diabetes of 10-19 years and ≥20 years compared to <10 years and a 28.22 
and 85.84 fold increased odds of STDR in the same sub-groups respectively.  For type 2 
diabetes the odds ratio of any DR and NSTDR was significantly higher (1.18 and 1.24 
respectively) in those aged over 66 years at diagnosis of diabetes than in subjects aged 55 
years or less at diagnosis.  However the odds ratio of STDR decreased (0.60 and 0.58) with 
increasing age at diagnosis of diabetes.  Males had an increased odds of all grades of DR 
compared to females.  The odds of all grades of DR increased with increasing duration of 
diabetes for any DR the odds increased by a factor of 1.60 with a known duration of diabetes 
of 5-9 years and almost 3.71 fold of 10 years or more compared to less than 5 years and for 
STDR the odds increased from 1.83 to 6.76 fold in the same subgroups respectively.  The use 
of insulin had ORs of 2.77 for any DR and 7.24 for STDR compared to those using diet 
alone. 
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Table 4 Multivariate logistic regression analysis for the association between age, gender and duration of diabetes with the presence of any DR, NSTDR and STDR 
in persons with type 1 and type 2 diabetes. 
Key: diabetes – Diabetes mellitus; Any DR – any diabetic retinopathy; NSTDR – Non sight-threatening diabetic retinopathy; STDR – Sight-threatening diabetic 
retinopathy; OR – Odds ratio; 95% CI – 95% confidence interval; OHA – Oral hypoglycaemic agent. 
No DR is the reference group NSTDR group excludes STDR and STDR group excludes NSTDR
Type 1 diabetes Type 2 diabetes 
 n Any DR  
OR (95%CI) 
NSTDR 
OR (95%CI) 
STDR  
OR (95%CI) 
 n Any DR  
OR (95%CI) 
NSTDR 
OR (95%CI) 
STDR 
OR(95%CI) 
Age at diagnosis 
of diabetes years: 
 
 
 
 
 
 
 
 
Age at diagnosis 
of diabetes 
years:  
 
 
 
 
 
 
 
 
≤12 1,725 1.00 1.00 1.00 ≤55 30,184 1.00 1.00 1.00 
13-23 1,703 
 
1.34 (1.12, 1.58) 1.30 (1.09, 1.55) 1.26 (0.95, 1.66) 56-66 29,437 0.97 (0.94, 1.01) 1.01 (0.98, 1.05) 0.60 (0.54, 0.66) 
≥24 1,575 0.40 (0.34, 0.47) 0.40 (0.33, 0.47) 0.30 (0.22, 0.40) ≥67 26,599 1.18 (1.13, 1.22) 1.24 (1.49, 1.29) 0.58 (0.51, 0.66) 
Male 2,721 1.20 (1.04, 1.38) 1.14 (0.99, 1.32) 2.02 (1.58, 2.57) Male 48,490 1.17 (1.14, 1.21) 1.16 (1.12, 1.20) 1.26 (1.16, 1.38) 
Duration of 
diabetes years: 
 
 
 
 
 
 
 
 
Duration of 
diabetes years:  
 
 
 
 
 
 
 
 
<10 1,876 1.00 1.00 1.00 <5 49,390 1.00 1.00  1.00  
10-19 1,341 7.90 (6.69, 9.32) 6.74 (5.68, 8.00) 28.22 (18.04, 44.15) 5-9 21,592 1.60 (1.54, 1.66) 1.59 (1.53, 1.65) 1.83 (1.63, 2.06) 
>/=20 1,786 20.60 (17.26, 24.59) 16.91 (14.10, 20.28) 85.84 (55.20, 133.50) >/=10 15,238 3.71 (3.56, 3.87) 47 (3.33, 3.63) 6.76 (6.07, 7.53) 
     Treatment of 
diabetes: 
  
 
 
 
 
 
Diet 26,025 1.00 1.00 1.00 
OHA 51,071 1.59 (1.53, 1.65) 1.54 (1.48, 1.60) 2.96 (2.55, 3.45) 
Insulin 8,226 2.77 (2.61, 2.94) 2.55 (2.40, 2.71) 7.24 (6.10, 8.59) 
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 DISCUSSION 
This study provides estimates of the baseline prevalence of DR for subjects over the age 
of 12 years and not receiving care at the hospital eye services for DR related reasons, 
when attending for the first time at the DRSSW.  In the population studied the 
prevalence of any DR, NSTDR and STDR in subjects with type 1 diabetes were 56.3, 
45.0 and 11.2% respectively and in type 2 diabetes were 30.9, 27.7 and 2.9% 
respectively.  The presence of both NSTDR and STDR were strongly associated with 
increasing duration of diabetes with either type 1 or type 2 diabetes and was also 
associated with insulin therapy in those with type 2 diabetes. 
 
The strength of this study is the large population size who underwent systematic 
screening using standardised quality assured procedures and equipment for both 
photography and grading.  Both graders and photographers were accredited.  The 
exclusion of subjects who did not participate in screening is a limitation.  The exclusion 
of those persons with diabetes under the care of the HES because of DR is likely to lead 
to an under-estimation, however currently the extent of this difference is not known.  
Although PPDR is the level at which referral to HES is required by screening 
programmes in the UK, it was excluded from the category of STDR in this study so that 
it was more comparable to the category of STDR reported in previous studies.  Also the 
limited availability of putative risk factors which included only duration and treatment 
of diabetes with glycaemic control, blood pressure and lipid status not collected by the 
DRSSW is a limitation and will be addressed in future studies.  
 
The comparison of the prevalence rates for DR between studies is inherently difficult 
due to the changing classification of diabetes over time and the different grading 
protocols employed, as well as differences in population characteristics (8, 27, 31-34).  
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Web appendix 1 shows the prevalence rates found in previous studies worldwide.  In 
other UK screening programmes the prevalence of any DR has been reported at 53.5% 
for type 1diabetes,(33) and 19.2 to 25.3% for type 2 diabetes,(3, 32, 33) which were 
lower than that seen in our study population at 56.0% and 30.3% respectively.  Also in 
comparison, in Iceland the prevalence of DR was slightly lower in type 1 diabetes and 
higher in type 2 diabetes at 51.7%,(34)  and 41.0%,(31) respectively. A recent meta-
analysis found a much higher prevalence of DR in type 1 diabetes at 77.3%,(27) and a 
slightly lower prevalence in type 2 diabetes at 25.2%.(27)  Retinal image capture 
(number of images and the use or not of mydriasis) may contribute to some of these 
differences as well as duration of diabetes.  Our study clearly demonstrates that 
increased duration of diabetes is associated with a higher prevalence of DR.  The 
prevalence of STDR previously reported in the UK has been 16.4% in type 1 diabetes 
and 1.9% and 6.0% in type 2 diabetes.(3, 32, 33)  In our study the prevalence of STDR 
was a little lower in persons with type 1 diabetes at 11.2%  Differences in the 
classification of STDR such as the inclusion or exclusion of PPDR and definitions of 
maculopathy may explain the differences.(32, 33)  We had essentially similar 
prevalence's of STDR at 2.9% in type 2 diabetes.  The Scottish screening programme 
reported the prevalence in 47,090 newly diagnosed type 2 diabetes and this short 
duration is likely to be the reason for the low prevalence of DR reported at 19.3% for 
any DR and 1.9% RDR.(3)  
 
Increasing duration of diabetes was the most significant risk factor for the presence of 
any DR, NSTDR and STDR in subjects with both types 1 and type 2 diabetes.  The odds 
ratios were much higher in type 1 diabetes compared to type 2 diabetes, however the 
duration of diabetes were also longer with subgroups of <10, 10-19 and ≥20 years 
compared to <5, 5-9 and ≥10 years respectively.  The risk of all grades of DR increased 
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with duration of diabetes being particularly high in those with diabetes duration of 20 
years or more for type 1 diabetes and 10 years or more for type 2 diabetes.   
In our study we observed an increased risk of all severities of DR associated with the 
use of insulin after adjusting for all other confounders. For type 2 diabetes this may 
reflect a more advanced disease state and we interpret this as likely to be an epi-
phenomenon and not a direct result of insulin therapy.   Both glycaemia and duration of 
diabetes have previously been shown to be highly associated with the presence of DR 
along with elevated blood pressure and cholesterol levels.(4, 8, 33, 35-38)   
 
To date this study represents the largest reported community-based national DR 
screening programme for detecting the presence of DR, especially STDR.  The findings 
will provide our policy makers with important information for planning eye care 
services, with the proviso that the prevalence of STDR may be underestimated because 
of those already within hospital eye services.  The strong association with disease 
duration demonstrates the importance of early detection and referral to a screening 
programme. The detection of STDR at an early stage is essential to ensure timely 
onward referral for further assessment and possible treatment to improved outcome.  
Detection of NSTDR provides the physician with an opportunity to improve, where 
necessary, glycaemic and blood pressure control to prevent the progression of DR.  A 
structured screening programme is expected to reduce blindness by 40% within 4 
years.(29)  Addressing issues of non-attendance currently at approximately 20% will 
contribute greatly to the success of such programmes to ensure optimal cost benefit of 
any DR screening service, especially poignant in times of austerity.
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